Clinical trial · Observational
Study of Predictive Factors of Chemoresistance in Ovarian Cancer
NCT02878122CI-TRIAL-00053312FaCliBioCCocompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Epithelial ovarian cancer (EOC) has a poor prognosis. EOC management requires debulking surgery and chemotherapy based on taxol and carboplatine. Initial response is often good, but most often a recurrence occurred in the first 18 months. Early recurrence signs chemoresistance and palliative treatment. The study of predictive clinical or biological factors is required to adapt therapeutic and develop new treatments.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cancer treatment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with epithelial ovarian cancer
- description
- Cancer treatment
- interventionNames
- Procedure: Cancer treatment
Primary outcomes (3)
- measure
- Chemoresistance defined by clinical recurrence
- timeFrame
- 6 months after the end of chemotherapy
- measure
- Chemoresistance defined by biological recurrence
- timeFrame
- 6 months after the end of chemotherapy
- measure
- Chemoresistance defined by radiological recurrence
- timeFrame
- 6 months after the end of chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patient \> 18 years of age * patient with histological proven epithelial ovarian cancer Exclusion Criteria: * patients who can not give their own consent * patients without ovarian cancer
References
Publications (0)
Data not yet available
No reference posted for this study.